66cl4 Syngeneic Model Overview
The 66cl4 syngeneic model is a moderately metastatic murine mammary carcinoma model derived from the same spontaneous BALB/c mammary tumor lineage as the 4T1 family. Positioned between the non-metastatic 67NR and the highly aggressive 4T1 models in metastatic potential, 66cl4 provides a balanced system for studying the mechanisms of controlled metastasis, immune regulation, and therapeutic response in an immunocompetent host. Following orthotopic implantation into the mammary fat pad of BALB/c mice, 66cl4 cells form consistent primary tumors that metastasize preferentially to the lungs, offering a biologically relevant model for post-primary dissemination and immune-mediated control of metastatic outgrowth.
This model maintains the full complement of host immune function, enabling evaluation of tumor-immune interactions, immune checkpoint modulation, and the microenvironmental factors that influence metastatic colonization. The 66cl4 model is particularly suited for research on the immunological determinants of micrometastatic dormancy and the efficacy of combination immunotherapies aimed at preventing metastatic recurrence.
Request a Custom Quote for 66cl4 Syngeneic ModelBiological and Molecular Characteristics
The 66cl4 cell line was isolated from the same spontaneous BALB/c mammary carcinoma that gave rise to the 4T1, 4T07, and 67NR lines. It retains a triple-negative receptor profile, being negative for estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, while exhibiting an epithelial morphology consistent with moderately differentiated carcinoma. The tumors display intermediate invasive capacity, forming localized primary lesions that generate circulating tumor cells and limited metastases, primarily to the lungs.
Molecular characterization reveals upregulated expression of angiogenic mediators such as VEGF and CXCL1, as well as inflammatory cytokines that attract macrophages and myeloid-derived suppressor cells (MDSCs). The immune microenvironment of 66cl4 tumors is characterized by a mix of pro-inflammatory and immunosuppressive elements, producing a balanced immune state that allows controlled metastatic growth suitable for mechanistic immunology studies.
| Parameter | Description |
|---|---|
| Host strain | BALB/c (female, 6–8 weeks) |
| Tumor origin | Spontaneous mammary carcinoma (mouse) |
| Receptor status | ER– / PR– / HER2– |
| Inoculation route | Orthotopic (mammary fat pad) or subcutaneous |
| Tumor take rate | >90% |
| Doubling time | Approximately 3–4 days in vivo |
| Metastatic sites | Primarily lungs; occasional liver or lymph node involvement |
| Immunophenotype | Balanced infiltration of T cells and macrophages |
| Common applications | Metastasis, immune checkpoint studies, combination therapy research |
In Vivo Model Development and Tumorigenicity
Orthotopic implantation of 66cl4 cells into the mammary fat pad of BALB/c mice consistently results in primary tumor development within 7–10 days post-inoculation. Tumors exhibit steady growth kinetics and reach measurable volumes suitable for therapeutic intervention within two weeks. Metastatic dissemination to the lungs typically occurs within four to five weeks, with minimal spread to other organs. This intermediate metastatic phenotype makes 66cl4 a valuable model for dissecting the stages of metastatic colonization and immune surveillance following dissemination.
Because the model preserves immune integrity, it is ideal for studies investigating how T cells, macrophages, and natural killer (NK) cells contribute to the control of both primary and secondary tumor sites. Subcutaneous implantation variants are used for direct measurement of tumor regression under immunotherapeutic intervention. The reproducibility of both local and metastatic growth in the 66cl4 model supports rigorous comparative analyses of immunotherapy efficacy and resistance mechanisms.
Request a Custom Quote for 66cl4 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histologically, 66cl4 tumors consist of densely packed epithelial cells arranged in solid nests surrounded by a collagen-rich stroma. The tumors display moderate mitotic activity, limited necrosis, and a partially organized vascular structure. Compared to 4T1 tumors, 66cl4 lesions show less stromal desmoplasia and reduced necrotic burden, reflecting their less aggressive biology. The metastatic nodules in the lungs are typically small and well-defined, making them suitable for histopathological quantification and immunological characterization.
Immunohistochemical analyses demonstrate a high proliferative index with robust Ki-67 staining. Moderate PD-L1 expression is observed on both tumor and stromal compartments, while CD3 and CD8 staining indicate moderate infiltration by T lymphocytes. F4/80 and CD11b markers confirm macrophage and myeloid cell presence, though in lower densities than in 4T1 tumors. The immune composition of 66cl4 tumors suggests a partially immune-reactive phenotype, making it an excellent system for studying therapies that modulate immune balance within the tumor microenvironment.
Preclinical Applications and Drug Response
The 66cl4 syngeneic model is an effective platform for preclinical evaluation of immunotherapies targeting metastatic breast cancer. It provides a controllable setting for testing immune checkpoint inhibitors, oncolytic viruses, cytokine-based therapies, and vaccine formulations. Checkpoint blockade targeting PD-1, PD-L1, and CTLA-4 pathways has shown measurable enhancement of T-cell activity in this system, often resulting in partial suppression of lung metastases rather than complete primary tumor regression. The model’s intermediate metastatic potential and preserved immune functionality make it well-suited for exploring therapeutic combinations that prevent the establishment of secondary lesions or prolong dormancy of disseminated tumor cells.
Additionally, the 66cl4 model serves as a key comparative element within the 4T1 tumor progression spectrum, bridging the gap between non-metastatic (67NR) and fully metastatic (4T1) variants. It provides critical insight into how incremental changes in tumor aggressiveness and immune regulation influence therapy outcomes, enabling the rational design of strategies to enhance immune surveillance and prevent metastatic relapse.
Request This Model
To request the 66cl4 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for 66cl4 Syngeneic Model